Arne Yndestad

MedicineImmunology and MicrobiologyBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance”.

Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance

Annals of the Rheumatic Diseases(2022)10.1136/ard-2022-222259

N/A

5.2DataRank · unranked

206 citations

Maya H Buch, Maxime Dougados, Deepak L. Bhatt, Jon T. Giles, Steven R. Ytterberg +11 more

Complement component C3 and the TLR co-receptor CD14 are not involved in angiotensin II induced cardiac remodelling

Biochemical and Biophysical Research Communications(2020)10.1016/j.bbrc.2020.01.018

N/A

0DataRank · unranked

4 citations

Camilla Schjalm, Per H. Nilsson, Margrethe Flesvig Holt, Jonas Øgaard, Egil Lien +7 more